Opternative introduces voice-activated digital eye exams for smartphones
Prior to the launch...
The Chicago-based online eye examination firm, Opternative, has announced the launch of a voice-activated eye exam for smartphones.
Prior to the launch of the latest exam, the firm’s initial test required the use of both a computer and smartphone.
“To build upon our vision of making eye care available to anyone, anywhere, anytime, we built the first web-based, conversational test that can be taken solely on a mobile browser,” stated Ayo Jimoh, Chief Technology Officer of Opternative.
“The technology helps elevate and increase access to vision care for patients across the globe.”
Google, IBM Watson, and Microsoft designed the voice recognition software used in the test, which allows users to renew prescriptions from their device despite any changes in the prescription.
The voice-recognition technology allows users to complete the eye test in under 15 minutes through its ability to easily and efficiently understand the patient’s voice.
Skin Analytics wins NHSX award for AI skin cancer tool
An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system.
NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion.
Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making.
In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog.
Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening.
DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.
Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.
Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges.
"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”